Renaissance Capital logo

Evaxion Biotech Priced, Nasdaq: EVAX

Danish Phase 1/2 biotech using AI to develop immuno-oncology therapies.

Industry: Health Care

Latest Trade: $8.21 0.00 (0.0%)

First Day Return: -1.1%

Return from IPO: -17.9%

Industry: Health Care

We are a clinical-stage AI-immunology platform company using our proprietary artificial intelligence, or AI, technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop novel immunotherapies for the treatment of various cancers, bacterial diseases and viral infections. Using the powerful AI technology of our PIONEER and EDEN platforms, we are currently developing four product candidates: EVX-01, for the treatment of metastatic and unresectable melanoma, non-small cell lung cancer, or NSCLC, and bladder cancer; EVX-02, for the adjuvant treatment of melanoma; EVX-03, for multiple cancer indications; and EVX-B1, a vaccine for the prevention of Staphylococcus aureus, or S. aureus (including Methicillin-resistant S. aureus, or MRSA), induced skin and soft tissue infections, or SSTI. Our two lead product candidates, EVX-01 and EVX-02, are both currently in Phase 1/2a trials. Our decision to move into a Phase 2b trial with these product candidates will be made based on the data readout from our ongoing trials. Upon completion of successful Phase 2b, proof-of-concept, or PoC, trials, we plan to monetize our current product candidates via out-licensing arrangements with pharmaceutical partners.
more less
IPO News for Evaxion Biotech
more
IPO Data
IPO File Date 01/08/2021
Offer Price $10.00
Price Range $10.00 - $12.00
Offer Shares (mm) 3.0
Deal Size ($mm) $30
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 02/04/2021
Offer Price $10.00
Price Range $10.00 - $12.00
Offer Shares (mm) 3.0
Deal Size ($mm) $30
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Copenhagen, Denmark
Founded 2008
Employees 35
Website www.evaxion-biotech.com